source
- Replimune argues its oncolytic virus plus checkpoint inhibitor benefits advanced melanoma patients at FDA advisory meetingReplimune presented data from its pivotal advanced melanoma trial to an FDA advisory committee. The company defended the trial design and results, emphasizing the added benefit of its oncolytic vi…
- Attovia, Braveheart Bio, and Vogenx aim to raise over $500M through combined IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have each filed IPO paperwork, setting price ranges that together target more than $500 million in gross proceeds from public investors. Braveheart…